American pharmaceutical companies Merck and Moderna announced Wednesday positive results, during the final phase of clinical trials for their experimental mRNA vaccine against skin cancer, demonstrating a statistically significant improvement in recurrence-free survival for patients with advanced melanoma who had undergone surgery, compared to a treatment with Keytruda alone.
In Plain English: The Clinical Takeaway
- Personalized mRNA Technology: The treatment is a “tailored” therapy, designed from the specific mutations of each patient’s tumor, which consists of dictating to the body’s cells how to manufacture proteins capable of triggering an immune response. The objective is to train and activate the patient’s immune system so that it recognizes and attacks cancer cells.
- Combination Therapy: The therapy is combined with the immunotherapy Keytruda from Merck.
- Phase 3 Milestone: This is the first announcement of positive phase 3 results for an mRNA-based cancer therapy.
Understanding the Phase 3 Trial and Mechanism of Action
The clinical trial evaluated 1,137 patients. According to announcements by Merck and Moderna, the experimental mRNA treatment—named “intismeran autogene”—was administered alongside the immunotherapy Keytruda. The mechanism of action relies on the technology of messenger ribonucleic acid (mRNA), which consists of dictating to the body’s cells how to manufacture proteins capable of triggering an immune response.
The therapy is designed from the specific mutations of each patient’s tumor. The objective is to train and activate the patient’s immune system so that it recognizes and attacks cancer cells.
Market Impact and Global Regulatory Path
The announcement was applauded on Wall Street: Moderna’s stock price was multiplied by more than 2.5, a gain of more than 40 billion dollars in market capitalization. Merck shares jumped more than 12%. The developers plan to present these data during an upcoming medical congress and to begin steps with authorities to request approval for this treatment.
Independent oncologists have noted the broader implications of these findings. Marco Gerlinger, an oncologist and professor at the Barts Cancer Institute in London, described the data as a “proof of concept that personalized cancer vaccines work.” Similarly, Lennard Lee, an oncologist and assistant professor at the University of Oxford, emphasized that while the findings are “very encouraging,” he awaits the publication of the complete data from these clinical trials.
Funding, Epidemiology, and Public Health Burden
The underlying research and clinical development are led by Merck and Moderna. Melanoma is one of the most lethal forms of skin cancer, with more than 330,000 new cases diagnosed worldwide in 2022, a figure that is growing.
| Parameter | Trial Detail |
|---|---|
| Therapeutic Agents | Intismeran autogene (mRNA) + Keytruda (pembrolizumab) |
| Target Indication | Advanced Melanoma (Post-Surgery) |
| Total Sample Size (N) | 1,137 patients |
| Sponsors | Merck and Moderna |
Contraindications & When to Consult a Doctor
The treatment is not yet commercially available. Stéphane Bancel, the leader of Moderna, stated: “For many years, the idea of creating an mRNA treatment designed specifically for an individual’s cancer was difficult to imagine. We are helping today to turn this vision into reality.”
Future Trajectory in Oncology
This is a major advance in the field of vaccines. It is a major first, as researchers have been trying for years to develop mRNA-based treatments against cancer.
References
Keep reading
- Emory University Sleep Disorders Study: Mild Cognitive Impairment Link
- 4 Longevity Mistakes Women Make That Impact Health After Menopause
- Congo Ebola Outbreak: 16,000+ Vaccine Doses Arrive to Combat Crisis (archyworldys.com)
- Dual-Oxygen Pancreatic Cancer Organoids Mirror Basal and Classical Subtypes (archynewsy.com)
